Cover Image
市场调查报告书

流感疫苗的全球市场分析

Global Influenza Vaccine Market Outlook 2022

出版商 RNCOS E-Services Pvt. Ltd. 商品编码 219637
出版日期 内容信息 英文 95 Pages
订单完成后即时交付
价格
Back to Top
流感疫苗的全球市场分析 Global Influenza Vaccine Market Outlook 2022
出版日期: 2016年06月01日 内容信息: 英文 95 Pages
简介

本报告提供全球流感疫苗市场相关详细的分析,疾病及治疗方法概要,及主要推动及阻碍市场要素,市场未来预测 (今后7年份),各地区的详细趋势,主要企业简介及开发中产品的信息汇整,为您概述为以下内容。

第1章 分析师的见解

第2章 调查手法

第3章 流感疫苗:简介

第4章 产业趋势与推动因素

  • 大流行病的发生数量增加
  • 可得性的扩大
  • 老年人口的增加
  • 通用流感疫苗的开发
  • 市场内地的产业合作

第5章 产业的相关课题

  • 临床实验方面、规定方面的课题
  • 认知度低
  • 医疗基础设施的不足

第6章 全球流感疫苗市场未来展望

  • 市场现状与未来展望
  • 主要的已上市疫苗
    • Fluzone/Vaxigrip
    • FluMist
    • Fluarix及Flulaval
    • Anflu
    • Fluvax/Afluria
    • Flucelvax及Fluvirin

第7章 主要地区的市场

  • 南北美洲
  • 欧洲
  • 亚太地区
    • 中国
    • 印度
    • 澳洲
    • 日本
  • 其他的国家 (RoW)

第8章 全球流感疫苗市场:开发平台分析

第9章 全球流感疫苗市场:价格分析

第10章 企业分析

  • Sanofi
    • 营业内容
    • 主要的财务指标
    • 流感疫苗产业
  • GlaxoSmithKline Plc (GSK)
  • 1CSL Ltd.
  • 1AstraZeneca Plc
  • Sinovac Biotech

图表

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录

The global influenza vaccine industry has reported a significant growth in recent years, and is presenting ample opportunities to the industry's players. With increasing pandemic as well as seasonal outbreak and rising awareness, the global influenza vaccine market is poised to scale newer acmes. Moreover, introduction of new vaccines, entry of new players, rising R&D investments, evolving government policies, and infrastructure projects are set to further boost the market's growth.

Since the H1N1 pandemic, worldwide authorities have started to adopt proactive approach in the vaccination process. Virus of previous pandemics are still circulating in the environment and in the coming future, they may be classified as strains to be updated in seasonal vaccines. Moreover, a large chunk of global population is affected by influenza-related problems. In such a scenario, huge opportunity lies for industry participants to tap the fast growing market.

The latest research by RNCOS titled, “Global Influenza Vaccine Market Outlook 2022” unfolds the market dynamics of the influenza vaccine market. The report shows the global influenza vaccine industry being segmented on the basis of major vaccine in the market. Followed by this, important geographies have been highlighted along with their current and future markets outlook till 2022. The report also covers advanced stage pipeline analysis of key players, which list down the influenza vaccines already in Phase III trials. The report identifies and highlights the segments that offer maximum opportunity for growth in the global influenza vaccine market.

Our industry analysts studied all the facets of the global influenza vaccine market to portray a crystal clear picture of the current as well as the expected market outlook. Major drivers and trends have been identified that are set to act as catalysts towards boosting the industry's growth, along with roadblocks hindering the market's growth.

The report further highlights the competitive landscape of the global influenza vaccine market, describing the business, financials, and influenza vaccine business of the major industry players. The section is therefore expected to clearly help the reader gain crucial insight into the key market players' performances and strategies for growth. Holistically, the research provides all the pre-requisite information for clients looking to make a debut in this industry, and facilitates them to formulate strategies while going for an investment/partnership in the global influenza vaccine industry.

Table of Contents

1. Analyst View

2. Research Methodology

3. Influenza Vaccine - Introduction

4. Industry Trends and Drivers

  • 4.1. Increasing Pandemic Outbreak
  • 4.2. Rising Affordability
  • 4.3. Rising Ageing Population
  • 4.4. Development of Universal Flu Vaccine
  • 4.5. Collaborations in the Market

5. Industry Challenges

  • 5.1. Testing and Regulatory Issues
  • 5.2. Low Awareness
  • 5.3. Lack of Medical and Healthcare Infrastructure

6. Global Influenza Vaccine Market Outlook 2022

  • 6.1. Current Market Overview and Future Outlook
  • 6.2. Major Marketed Vaccines
    • 6.2.1. Fluzone/Vaxigrip
    • 6.2.2. FluMist
    • 6.2.3. Fluarix and Flulaval
    • 6.2.4. Anflu
    • 6.2.5. Fluvax/Afluria
    • 6.2.6. Flucelvax and Fluvirin

7. Key Geographical Market

  • 7.1. Americas
  • 7.2. Europe
  • 7.3. Asia Pacific
    • 7.3.1. China
    • 7.3.2. India
    • 7.3.3. Australia
    • 7.3.4. Japan
  • 7.4. Rest of the World

8. Global Influenza Vaccine Market: Pipeline Analysis

9. Global Influenza Vaccine Market: Pricing Analysis

10. Competitive Assessment

  • 10.1. Sanofi
    • 10.1.1. Business Description
    • 10.1.2. Financial Overview
    • 10.1.3. Influenza Vaccine Business
  • 10.2. GlaxoSmithKline Plc (GSK)
    • 10.2.1. Business Overview
    • 10.2.2. Financial Overview
    • 10.2.3. Influenza Vaccine Business
  • 10.3. CSL Ltd.
    • 10.3.1. Business Overview
    • 10.3.2. Financial Overview
    • 10.3.3. Influenza Vaccine Business
  • 10.4. AstraZeneca Plc
    • 10.4.1. Business Overview
    • 10.4.2. Financial Overview
    • 10.4.3. Influenza Vaccine Business
  • 10.5. Sinovac Biotech
    • 10.5.1. Business Overview
    • 10.5.2. Financial Overview
    • 10.5.3. Influenza Vaccine Business

List of Figures:

  • Figure 6-1: Global - Influenza Vaccine Sales (Million Doses), 2015 & 2022
  • Figure 6-2: Global - Influenza Vaccine Market (Billion US$), 2015-2022
  • Figure 6-3: Global - Influenza Vaccine Market by Players (%), 2015
  • Figure 6-4: Global - Fluzone/Vaxigrip Sales (Million US$), 2011-2015
  • Figure 6-5: Global - FluMist Sales (Million US$), 2011-2015
  • Figure 6-6: Global - Fluarix and FluLaval Sales (Million US$), 2011-2015
  • Figure 6-7: Global - Anflu Sales (Million Doses), 2011-2015
  • Figure 6-8: Global - Anflu Sales (Million US$), 2011-2015
  • Figure 6-9: Global - Afluria/Fluvax Sales (Million US$), 2013-2015
  • Figure 6-10: Global - Flucevax and Fluvirin Sales (Million US$), 2013-2015
  • Figure 7-1: Global - Influenza Vaccine Market by Region (%), 2015
  • Figure 7-2: US - Influenza Vaccine Sales (Million Doses), 2011-12 to 2015-16
  • Figure 7-3: Americas - Influenza Vaccine Market by Players (%), 2015
  • Figure 7-4: Americas - Influenza Vaccine Market (Billion US$), 2015-2022
  • Figure 7-5: Europe - Influenza Vaccine Market by Players (%), 2015
  • Figure 7-6: Europe - Influenza Vaccine Market (Billion US$), 2015-2022
  • Figure 7-7: Europe - Seasonal Influenza Vaccination Coverage in Older Age Group by Country (%), 2011-12 & 2012-13
  • Figure 7-8: Asia-Pacific - Influenza Vaccine Market by Players (%), 2015
  • Figure 7-9: Asia Pacific - Influenza Vaccine Market (Billion US$), 2015-2022
  • Figure 7-10: Rest of the World - Influenza Vaccine Market (Billion US$), 2015-2022
  • Figure 8-1: Global - Breakup of Influenza Vaccine Pipeline by Type of Vaccine
  • Figure 10-1: Sanofi - Breakup of Total Revenues by Business Segment (%), 2015
  • Figure 10-2: Sanofi Pasteur - Breakup of Vaccine Segment by Type (%), 2015
  • Figure 10-3: Sanofi Pasteur - Breakup of Total Influenza Vaccine Revenues by Geography (%), 2015
  • Figure 10-4: GlaxoSmithKline Plc - Breakup of Total Revenues by Business Segment (%), 2015
  • Figure 10-5: GlaxoSmithKline Plc - Breakup of Vaccine Segment by Type (%), 2015
  • Figure 10-6: GlaxoSmithKline Plc - Breakup of Total Influenza Vaccine Revenue by Geography (%), 2015
  • Figure 10-7: CSL Ltd - Breakup of Total Revenues by Business Segment (%), 2015
  • Figure 10-8: CSL Ltd - Breakup of bioCSL Revenues by Product Type (%), 2015
  • Figure 10-9: AstraZeneca Plc - Breakup of Total Revenues by Business Segment (%), 2015
  • Figure 10-10: AstraZeneca Plc - Breakup of Infection Segment by Type (%), 2015
  • Figure 10-11: AstraZeneca Plc - Breakup of Total Influenza Vaccine Revenues by Geography (%), 2015
  • Figure 10-12: Sinovac Biotech - Breakup of Vaccine Revenue by Type (%), 2015

List of Tables:

  • Table 7-1: US - Major Influenza Vaccines & Manufacturers (2015-16)
  • Table 7-2: US - Percentage of Children Who Received Influenza Vaccine (2015-16)
  • Table 7-3: US - Percentage of Adults Who Received Influenza Vaccine (2015-16)
  • Table 7-4: US - Number of Pediatric Deaths in Flu Season (2005-06 to 2015-16)
  • Table 7-5: Europe - Major Influenza Vaccines & Manufacturers (2015-16)
  • Table 7-6: China - Vaccine Classification
  • Table 7-7: Australia - Major Influenza Vaccines & Manufacturer (2016)
  • Table 8-1: Global - Influenza Vaccine Pipeline Analysis
  • Table 9-1: Global - Major Influenza Vaccines Cost/Dose (US$), 2016-17
  • Table 10-1: Sanofi - Key Financials (Million US$), 2013-2015
  • Table 10-2: Sanofi - Influenza Vaccines Offered
  • Table 10-3: GlaxoSmithKline Plc - Key Financials (Million US$), 2013-2015
  • Table 10-4: GlaxoSmithKline Plc - Influenza Vaccines Offered
  • Table 10-5: CSL Ltd. - Key Financials (Million US$), 2013-2015
  • Table 10-6: CSL - Influenza Vaccine Portfolio before Merger
  • Table 10-7: CSL - Influenza Vaccine Portfolio after Merger
  • Table 10-8: AstraZeneca Plc - Key Financials (Million US$), 2013-2015
  • Table 10-9: AstraZeneca Plc - Influenza Vaccines Offered
  • Table 10-10: Sinovac Biotech - Key Financials (Million US$), 2013-2015
  • Table 10-11: Sinovac Biotech - Influenza Vaccines Offered
Back to Top